Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials — W BROOKS GENTRY (INTERVEXIO
InterveXion is developing an anti-methamphetamine (METH) monoclonal antibody called IXT-m200 for the treatment of METH use disorders. Single doses of IXT-m200 have been well-tolerated in healthy volun
| Project title | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials |
|---|---|
| Project number | 5U01DA051078-02 |
| PI name | W BROOKS GENTRY |
| Institution | INTERVEXION THERAPEUTICS, LLC |
| Funding mechanism | U01 |
| Agency | NIDA |
| Award amount | $3.17M |
| Fiscal year | 2021 |
| Project start | 2020-05-01T00:00:00 |
| Project end | 2023-02-28T00:00:00 |
| Abstract | InterveXion is developing an anti-methamphetamine (METH) monoclonal antibody called IXT-m200 for the treatment of METH use disorders. Single doses of IXT-m200 have been well-tolerated in healthy volun |
| Key terms | <Active Sites><Advanced Development><Adverse Experience><Adverse event><Affinity><Annual Reports><An |
$799/mo
Try GrantRadar →